Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 185   

Articles published

GSK 1,654.50 +12.00 (0.73%)
price chart
Glaxo, AstraZeneca lead UK stocks to two-week high
LONDON (MarketWatch) - U.K. equities advanced Tuesday, with AstraZeneca PLC gaining on speculation the British drug maker will receive a takeover bid, while GlaxoSmithKline PLC shares rose as the pharmaceutical heavyweight made a couple of its ...
U.K. Stocks Climb as M&A Activity Spur AstraZeneca, Glaxo  Bloomberg
Europe's Stocks to Watch: Novartis, GlaxoSmithKline, AstraZeneca  Wall Street Journal (blog)
Related articles »  
GlaxoSmithKline Plc (GSK) Is Up Sharply After Novartis Deal
GlaxoSmithKline plc (GSK: Quote) announced Tuesday morning that it agreed to sell its oncology products to Novartis (NVS: Quote) for US$14.5 billion payment and up to US$1.5 billion contingent on a development milestone.
GlaxoSmithKline plc's Dividends Set To Reach 5.4%!
The latest big news for GlaxoSmithKline (LSE: GSK) (NYSE: GSK) is its new deal with Novartis - some assets will be transferred in one direction, others in the opposite direction, and there will be a new joint venture to deal with a lot of the two ...
Novartis Signs Deals with Glaxo, Lilly
Under the terms of the agreement, Novartis would acquire GlaxoSmithKline's oncology products for $14.5 billion and up to $1.5 billion as milestone payments.
How GlaxoSmithKline plc (GSK) and These Stocks Rescued Biotech Sector ...
GlaxoSmithKline plc (NYSE:GSK) declared on Tuesday morning that it decided to sell its oncology products to Novartis (NVS) in a bid of US$14.5 billion payment and almost US$1.5 billion contingent on a development milestone.
Novartis, Glaxo in deal to transform firms, industry
London/Mumbai: Novartis AG agreed to buy GlaxoSmithKline Plc's (GSK's) cancer-drug business for as much as $16 billion, form a consumer-health venture with GSK and sell its animal-health operation to Eli Lilly and Co.
ADR Shares End Mixed; Novartis, Glaxo, Philips Shares Active
... (PHG, PHIA.AE). Drug giants Novartis and GlaxoSmithKline unveiled a series of transactions worth more than $20 billion that fundamentally transform both companies, focusing Novartis's scope without significantly hitting its revenue and turning ...
Novartis-Glaxo Cancer, Animal Unit Swaps Show Industry Overhaul
April 22 (Bloomberg) -- A flurry of billion-dollar deals announced today including a swap of cancer and vaccine drugs between Novartis AG and GlaxoSmithKline Plc will reshape the pharmaceutical industry as it looks to cut costs and may herald another ...
Is GlaxoSmithKline plc Just A Tracker Fund In Disguise?
I hold Glaxo, and I hold a tracker fund, the HSBC FTSE 100 Index. Both have served me well. But why hold both? After all, 4.4% of my tracker fund is actually made up of Glaxo, with its massive �80 billion market cap. The tracker gives me a dab of ...
Related articles »  
GlaxoSmithKline plc Stumbles But It's Still A Buy
Drug-maker GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has announced its third setback in almost as many days with news of failed drugs trials.
GlaxoSmithKline throws in towel on lung cancer vaccine trial  Reuters
Related articles »